Eli Lilly's most recent trend suggests a bullish bias. One trading opportunity on Eli Lilly is a Bull Put Spread using a strike $101.00 short put and a strike $96.00 long put offers a potential 11.61% return on risk over the next 3 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $101.00 by expiration. The full premium credit of $0.52 would be kept by the premium seller. The risk of $4.48 would be incurred if the stock dropped below the $96.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Eli Lilly is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Eli Lilly is bullish.
The RSI indicator is above 80 which suggests that the stock is in overbought territory.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Eli Lilly
Eli Lilly Stock History
Fri, 10 Aug 2018 12:08:00 +0000
Here's how this company became a biopharma giant, and what could be in store next for investors.
Analysts’ Recommendations for Pfizer on August 6
Thu, 09 Aug 2018 14:30:21 +0000
Analysts expect Pfizer’s (PFE) adjusted EPS to be $2.99 on revenue of $54.3 billion in 2018, a 3.4% rise compared to $52.5 billion in 2017. Analysts also expect a 10.9% rise in the company’s adjusted net income during 2018, mainly due to a fall in its selling, general, and administrative expenses as well as its lower research and development expenses as a percentage of its sales.
Celldex (CLDX) Q2 Earnings and Revenues Surpass Estimates
Thu, 09 Aug 2018 14:04:02 +0000
Celldex (CLDX) reports narrower-than-expected loss in Q2. Revenues fell due to reduced contract revenues.
A Look at Recent Developments at Pfizer
Thu, 09 Aug 2018 11:30:28 +0000
Pfizer’s (PFE) Innovative Health business is focused on developing and commercializing medicines, vaccines, and consumer healthcare products, while its Essential Health business includes legacy brands and generic products, research and development, and its contract manufacturing business.
Eli Lilly Raised Its Non-GAAP Earnings Guidance for Fiscal 2018
Wed, 08 Aug 2018 17:10:02 +0000
In Eli Lilly’s (LLY) second-quarter earnings conference call, the company raised its fiscal 2018 non-GAAP EPS guidance from the previously projected range of $5.10–$5.20 to $5.40–$5.50. If we consider the midpoint of the guidance range, the guidance implies a rise of 27% YoY (year-over-year) in the company’s non-GAAP EPS in fiscal 2018. Eli Lilly reduced its fiscal 2018 GAAP EPS guidance from the previously projected range of $4.52–$4.62 to $3.19–$3.29 due to higher charges associated with in-process research and development related to the acquisition of ARMO BioSciences.
Related Posts
Also on Market Tamer…
Follow Us on Facebook